
Precursors Through First Treatment - Houston March 26, 2022 Myeloma Round Table
It is estimated that about 80% of myeloma patients never have direct or indirect contact with a specialist. Yet studies have shown that patients whose treatment is supervised by a specialist have better outcomes as compared to those who do not.
The topic of this program will be: Treating myeloma and precursor conditions with the latest myeloma therapies in 2022.
Thanks to our Round Table sponsors

Jennifer Ahlstrom

Greg Brozeit

Krina Patel, MD, MSc

Elisabet Manasanch, MD

Robert Orlowski, MD, PhD

Muzaffar Qazilbash, MD
Mazaffar Qazilbash, MD, is Director of Myeloma Transplantation and Cellular Therapy and Professor in the Department of Stem Cell Transplantation in the…

Hans Lee, MD
Hans Lee, MD, is Assistant Professor in the Department of Lymphoma/Myeloma and Director of Multiple Myeloma Clinical Research at the MD Anderson Cancer Center…

Rebecca Lu, RN, FNP-BC